A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2028-02-08
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to:
- Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with
pembrolizumab in participants with advanced solid tumors
- Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as
monotherapy and in combination with pembrolizumab in participants with advanced solid
tumors.